Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaire Cooperman Isn’t Gambling With These Stocks Anymore

Page 1 of 2

Leon Cooperman’s Omega Advisors recently filed a 13G with the SEC, reporting the sale of its stake in Caesars Entertainment Corp (NASDAQ:CZR). As per its 13F filing for the reporting period of March 31, 2015, the investment manager had a position in Caesars Entertainment consisting of 7.33 million shares valued at $77.21 million. What is of more interest is that Caesars Entertainment Corp (NASDAQ:CZR) is not the only company whose stock have been sold by the investment manager in recent months. Omega Advisors sold its entire stake in HCA Holdings Inc (NYSE:HCA), Gilead Sciences, Inc. (NASDAQ:GILD), Cabot Oil & Gas Corporation (NYSE:COG), and Apple Inc. (NASDAQ:AAPL), as reported in its most recent 13F filing. We’ll take a look at these sales in this article and try to determine why Cooperman has moved out of them.

Groupon, Alibaba, is GRPN a good stock to buy, is BABA a good stock to buy, Leon Cooperman, Omega Advisors,

We follow hedge funds like Omega Advisors because our research has shown that their stock picks historically managed to generate alpha even though the filings are up to 45-days delayed. We used a 60-day delay in our back tests to be on the safe side and our research showed that the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Total Return Index by an average of 95 basis points per month between 1999 and 2012. After adjusting for risk, our calculations revealed that these stocks’ monthly alpha was 80 basis points. We have also been sharing and tracking the performance of these stocks since the end of August 2012, during which time they have returned 142%, outperforming the S&P 500 ETF by nearly 84 percentage points (see more details here).

Leon Cooperman’s latest 13G mentioned the sale of its entire stake in Caesars Entertainment Corp (NASDAQ:CZR) on June 5, 2015. After considering the stock market performance of the casino/entertainment company, Cooperman’s decision seems justified, as the shares of Caesars Entertainment have declined 59.22% year-to-date. On top of its dismal stock market performance, the entertainment company is facing multiple lawsuits, including one brought against it by UMB Bank, with potential damages exceeding $6 billion. According to the bank, Caesars Entertainment Corp (NASDAQ:CZR) breached the terms of its first-lien notes by notwithstanding the guarantee of its operating unit’s obligations. The hospitality service company said that the lawsuit is without merit and its restructuring agreement with the fund holders stays intact. Paulson & Co and Mason Capital Management are among investment managers that hold substantial positions in the hospitality service provider.

HCA Holdings Inc (NYSE:HCA) is another company in which Cooperman sold out of his entire stock position. As per the 13F filing of Omega Advisors, the investment manager disposed of 1.09 million shares of the healthcare service company. What makes it a surprising decision is the fact that the shares of HCA Holdings Inc (NYSE:HCA) have improved 13.64% year-to-date. The stock reached its all-time high earlier this month at $85.06 per share and is among the top gainers in the healthcare industry over the last three months. Lone Pine Capital and Glenview Capital are among the major stockholders of HCA Holdings Inc (NYSE:HCA).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!